CAS |
133053-19-7 |
English Name |
Go 6983 |
Synonyms |
G6983;PHORBOL; |
Molecular Formula |
C26H26N4O3 |
Molecular Weight |
442.51 |
Solubility |
Soluble in DMSO |
Purity |
≥98% |
Appearance |
Solid |
Storage |
Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL |
MFCD04040031 |
SMILES |
O=C(C(C1=CN(CCCN(C)C)C2=C1C=C(OC)C=C2)=C3C4=CNC5=C4C=CC=C5)NC3=O |
InChIKey |
LLJJDLHGZUOMQP-UHFFFAOYSA-N |
InChI |
InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5,7-10,13-15,27H,6,11-12H2,1-3H3,(H,28,31,32) |
PubChem CID |
3499 |
Target Point |
PKC |
Passage |
TGF-beta/Smad;Epigenetics |
Background |
Go 6983 is a potent PKC inhibitor. |
Biological Activity |
Go 6983 是一种有效的 PKC 抑制剂,能够作用于 PKCα,PKCβ,PKCγ,PKCδ 和 PKCζ,IC50 值分别为 7 nM,7 nM,6 nM,10 nM 和 60 nM[1-3]。 |
In Vitro |
Go 6983抑制PKCμ,IC50为20μM,Go 6983可以抑制pther PKC同工酶,IC50值为7~60 nM [1]。与I/R + PMN心脏相比,Go 6983(100 nM)显著降低了PMN对内皮的粘附和向心肌的浸润,并显著抑制了大鼠心脏中PMNs的超氧化物释放90 +/- 2%[2]。与心脏保护性Go 6983浓度(50和100 nM)相比,Go 6983(200 nM)具有降低的心脏保护作用,尽管抑制PMN超氧化物释放99%[3]。 |
Kinase Experiment |
磷酸化反应在总体积100μL中进行,含有缓冲液C(50mM Tris-HCl,pH7.5,10mMβ-巯基乙醇),4mM MgCl2,10μgPS,100nM TPA,5μLSf158。细胞提取物作为重组PKCμ或Sf9细胞提取物的来源,作为其他重组PKC同工酶的来源,10μg作为底物的syntide 2,和含有1μCi[γ-32P] ATP的35μMATP。在一些实验中,省略了PS和TPA,或者添加了文中指出的浓度的各种抑制剂。在30℃温育10分钟后,通过将50μL测定混合物转移到20mm见方的磷酸纤维素纸上终止反应,将其在去离子水中洗涤3次并在丙酮中洗涤两次。每种纸上的放射性通过液体闪烁计数确定。 |
Data Literature Source |
[1]. Gschwendt M,et al. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett,1996,392(2),77-80. [2]. Peterman EE,et al. G0 6983 exerts cardioprotective effects in myocardial ischemia/reperfusion. J Cardiovasc Pharmacol,2004,43(5),645-656. [3]. Young LH,et al. G0 6983: a fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury. Cardiovasc Drug Rev,2005,23(3),255-272 |
Unit |
Piece |
Specification |
5mg |